Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800% This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million More This biotechnology firm advances targeted cancer therapies, leveraging genetic insights and strategic partnerships in oncology.
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story This biotech firm develops therapies for rare, complement-driven diseases, with a focus on autoimmune and inflammatory conditions.
This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch Cogent Biosciences develops targeted therapies for genetically defined diseases, focusing on precision medicine for rare cancers.
This Specialized Heart Monitor Maker Just Caught the Eye of a Major Healthcare Fund RTW Investments loads up on iRhythm Holdings with 1.18M Shares Worth $210 million. iRhythm delivers wearable cardiac monitoring and analytics solutions to healthcare providers and at-risk patients.
2 Under-the-Radar Stocks to Buy and Hold These biotechs are slowly making a name for themselves.
Investor Buys Up $81 Million in Praxis Stock as Shares Soar Over 300% in One Year Praxis Precision Medicines develops therapies for neurological and psychiatric disorders, aiming to address unmet needs in the CNS market.
This Fund Bet Nearly $40 Million on GRAIL Last Quarter. The Stock Just Plunged Over 50% GRAIL develops advanced cancer detection technologies, serving healthcare providers and individuals seeking early diagnostic solutions.
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline.
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors.
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs.
Why Madrigal Pharmaceuticals Stock Slumped on Tuesday The stock has had quite the run following Rezdiffra's 2024 approval by the FDA.
